Skip to main content

Advertisement

SpringerLink
Log in

Dexibuprofen: pharmacology, therapeutic uses and safety

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Dexibuprofen is the single pharmacologically effective enantiomer of rac-ibuprofen. Racibuprofen and dexibuprofen differ in their physico-chemical properties, in terms of their pharmacological properties and their metabolic profiles. Several clinical trials and post-marketing surveillance studies were performed to broaden the findings on dexibuprofen. In the last 5 years 4836 patients have been exposed to dexibuprofen in clinical trials and PMS trials. Only in 3.7% of patients adverse drug reactions have been reported and 3 serious adverse drug reactions (0.06%) were observed. In the dose ratio of 1 : 0.5 (rac-ibuprofen vs. dexibuprofen) at least equivalent efficacy was proven in acute mild to severe somatic and visceral pain models. Dexibuprofen has proven at least comparable efficacy to diclofenac, naproxen and celecoxib and has shown a favourable tolerability. The results suggest that dexibuprofen processed in a special crystal form is a safe and effective treatment for different pain conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Dionne, R. A. and McCullagh, L. (1998). Enhanced analgesia and supression of plasma ¯-endorphin by the S(+)-isomer of ibupropfen, Clin. Pharmacol. Ther. 63, 694–701.

    PubMed  Google Scholar 

  • Evans, A. M. (1992). Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steriodal anti-inflammatory drugs, Eur. J. Clin. Pharmacol. 42, 237–256.

    PubMed  Google Scholar 

  • Evans, A. M. (1996). Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen, J. Clin. Pharmacol. 36, S7–S15.

    Google Scholar 

  • Hawel, R., Klein, G., Singer, F., et al. (2003). Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip, Int. J. Clin. Pharmacol. Ther. 41, 153–164.

    PubMed  Google Scholar 

  • Jamali, F. and Kunz-Dober, C. M. (1999). Pain-mediated altered absorption and metabolism of ibuprofen: an explanationfor decreased serumenantiomer concentrationafter dental surgery, Br. J. Clin. Pharmacol. 47, 391–396.

    PubMed  Google Scholar 

  • Janjikhel, R. K. and Bricker, J. D. (1999). Stereoselective dispositionof sustained release microphers of ibuprofen enantiomers in rats: II. Acute gastrointestinal toxicity, Drug Deliv. 6, 163–170.

    Google Scholar 

  • Klein, G., Neff, H., Kullich, W., et al. (1992). S(+) versus racemic ibuprofen, Lancet 339, 681.

    Google Scholar 

  • Langman, M. J. S., Weil, J. and Wainright, P. (1994). Risks of bleeding peptic ulcer associated with individual non-steriodal anti-inflammatory drugs, Lancet 343, 1075–1078.

    PubMed  Google Scholar 

  • Leising, G., Resel, R., Stelzer, F., et al. (1996). Physical aspects of dexibuprofen and racemic ibuprofen, J. Clin. Pharmacol. 36, 3S–6S.

    Google Scholar 

  • Morihara, T., Chu, T., Ubeda, O., et al. (2002). Selective inhibition of Aβ42 production by NSAID R-enantiomers, J. Neurochem. 83, 1009–1012.

    PubMed  Google Scholar 

  • Rainsford, K. D. (Ed.) (1999). Pharmacology and toxicology of ibuprofen, in: Ibuprofen, a critical bibliographic review, pp. 145–275, Taylor & Francis, London.

  • Rudy, A. C., Bradley, J. D., Ryan, S. I., et al. (1992). Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients, Ther. Drug Monitoring 14, 464–470.

    Google Scholar 

  • Singer, F., Mayrhofer, F., Klein, G., et al. (2000). Evaluation of the efficacy and dose-response relationship of dexibuprofen(S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Int. J. Clin. Pharmacol. Ther. 38, 15–24.

    PubMed  Google Scholar 

  • Tseng, C.-C. and Wolfe, M. M. (2000). Nonsteriodal anti-inflammatory drugs, Adv. Gastroenterol. 84, 1329–1344.

    Google Scholar 

  • Vanderhoek, J. Y. and Bailey, M. J. (1984). Activation of a 15-lipoxygenase/ leukotriene pathway in human polymorphonuclear leucocytes by the anti-inflammatory agent ibuprofen, J. Biol. Chem. 259, 6752–6756.

    PubMed  Google Scholar 

  • Vanderhoek, J. Y., Ekborg, S. L. and Bailey, M. J. (1984). Effects of cell growth, differentiation, and transformation: clinical involvement of leucotrienes, J. Allergy Clin. Immunol. 74, 412–416.

    PubMed  Google Scholar 

  • Villanueva, M., Heckenberger, H., Palmer, S. M., et al. (1993). Equipotent inhibition by R-(–)-, S-(+)-and racemic ibuprofen of human polymorphonuclear cell function in vitro, Br. J. Clin. Pharmacol. 35, 235–242.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department, Gebro Pharma GmbH, A-6391, Fieberbrunn, Austria

    S. T. Kaehler & W. Phleps

  2. Research and Development Department, Gebro Pharma GmbH, Fieberbrunn, Austria

    E. Hesse

Authors
  1. S. T. Kaehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Phleps
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Hesse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaehler, S.T., Phleps, W. & Hesse, E. Dexibuprofen: pharmacology, therapeutic uses and safety. Inflammopharmacology 11, 371–383 (2003). https://doi.org/10.1163/156856003322699555

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1163/156856003322699555

Search

Navigation